Imatinib is an effective drug for treating the majority of CML patients, which is mostly attributed to the blockade of the known growth-promoting properties of BCR-ABL1, such as activation of the downstream MAPK, AKT, and STAT pathways. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.